55 related articles for article (PubMed ID: 4147120)
1. Metabolism of salicylazosulfapyridine in healthy subjects and in patients with ulcerative colitis. Effects of colectomy and of phenobarbital.
Schröder H; Lewkonia RM; Price Evans DA
Clin Pharmacol Ther; 1973; 14(5):802-9. PubMed ID: 4147120
[No Abstract] [Full Text] [Related]
2. Letter: Value of uncontrolled trials in use of sulfasalazine.
Goldstein F
N Engl J Med; 1975 Aug; 293(9):455. PubMed ID: 239348
[No Abstract] [Full Text] [Related]
3. Individual variation in first-pass metabolism.
Tam YK
Clin Pharmacokinet; 1993 Oct; 25(4):300-28. PubMed ID: 8261714
[TBL] [Abstract][Full Text] [Related]
4. Amino acid derivatives of 5-ASA as novel prodrugs for intestinal drug delivery.
Clerici C; Gentili G; Boschetti E; Santucci C; Aburbeh AG; Natalini B; Pellicciari R; Morelli A
Dig Dis Sci; 1994 Dec; 39(12):2601-6. PubMed ID: 7995185
[TBL] [Abstract][Full Text] [Related]
5. New salicylates as maintenance treatment in ulcerative colitis.
Järnerot G
Gut; 1994 Sep; 35(9):1155-8. PubMed ID: 7959217
[No Abstract] [Full Text] [Related]
6. The association of the slow acetylator phenotype with bladder cancer.
Evans DA; Eze LC; Whibley EJ
J Med Genet; 1983 Oct; 20(5):330-3. PubMed ID: 6644762
[TBL] [Abstract][Full Text] [Related]
7. Survey of the human acetylator polymorphism in spontaneous disorders.
Evans DA
J Med Genet; 1984 Aug; 21(4):243-53. PubMed ID: 6387123
[TBL] [Abstract][Full Text] [Related]
8. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
Azadkhan AK; Truelove SC; Aronson JK
Br J Clin Pharmacol; 1982 Apr; 13(4):523-8. PubMed ID: 6121576
[TBL] [Abstract][Full Text] [Related]
9. Sulphasalazine and male infertility: reversibility and possible mechanism.
Toovey S; Hudson E; Hendry WF; Levi AJ
Gut; 1981 Jun; 22(6):445-51. PubMed ID: 6114897
[TBL] [Abstract][Full Text] [Related]
10. Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease.
West B; Lendrum R; Hill MJ; Walker G
Gut; 1974 Dec; 15(12):960-5. PubMed ID: 4155692
[TBL] [Abstract][Full Text] [Related]
11. Effects of ischaemic heart disease, Crohn's disease and antimicrobial therapy on the pharmacokinetics of sulphinpyrazone.
Strong HA; Angus R; Oates J; Sembi J; Howarth P; Renwick AG; George CF
Clin Pharmacokinet; 1986; 11(5):402-10. PubMed ID: 3780113
[TBL] [Abstract][Full Text] [Related]
12. Stability of disodium azodisalicylate (olsalazine) and metabolites in urine and faeces stored at different temperatures.
van Hogezand RA; van Schaik A; van Hees PA; van Tongeren JH
Eur J Drug Metab Pharmacokinet; 1988; 13(4):261-5. PubMed ID: 3243321
[TBL] [Abstract][Full Text] [Related]
13. Chloroquine decreases oral-caecal transit time.
Adjepon-Yamoah KK; Woolhouse NM; Ofori-Adjei D; Nortey LN
Br J Clin Pharmacol; 1985 Oct; 20(4):425-6. PubMed ID: 2866787
[No Abstract] [Full Text] [Related]
14. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz U
Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
[TBL] [Abstract][Full Text] [Related]
15. The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration.
Shaffer JL; Houston JB
Br J Clin Pharmacol; 1985 Apr; 19(4):526-8. PubMed ID: 2859874
[No Abstract] [Full Text] [Related]
16. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).
Lauritsen K; Laursen LS; Rask-Madsen J
Clin Pharmacokinet; 1990 Aug; 19(2):94-125. PubMed ID: 2199130
[TBL] [Abstract][Full Text] [Related]
17. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
Hanauer SB; Stathopoulos G
Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
[TBL] [Abstract][Full Text] [Related]
18. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
Taggart AJ; McDermott BJ; Roberts SD
Clin Pharmacokinet; 1992 Oct; 23(4):311-20. PubMed ID: 1356683
[TBL] [Abstract][Full Text] [Related]
19. Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.
Pagliaro LA; Benet LZ
J Pharmacokinet Biopharm; 1975 Oct; 3(5):333-83. PubMed ID: 1107513
[No Abstract] [Full Text] [Related]
20. A pharmacological method of measuring mouth caecal transit time in man.
Kennedy M; Chinwah P; Wade DN
Br J Clin Pharmacol; 1979 Oct; 8(4):372-3. PubMed ID: 41551
[No Abstract] [Full Text] [Related]
[Next] [New Search]
